Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage precision medicine oncology company, announced the successful closing of its previously announced oversubscribed private placement financing, raising approximately $30 million in gross proceeds. The financing, which closed on March 31, 2026, was led by Soleus Capital with participation from new investors including Vestal Point Capital and Squadron Capital Management, as well as existing investors and insiders of the company. The funds will be utilized for general corporate purposes and to support the ongoing development of APR-1051, an oral small-molecule inhibitor of WEE1 kinase. This funding is expected to accelerate the advancement of the ongoing ACESOT-1051 study, which aims to evaluate APR-1051 in biologically selected tumor populations, particularly in patients with uterine serous carcinoma and platinum-resistant ovarian cancer. Oren Gilad, Ph.D., President and CEO of Aprea, expressed confidence in the financing, stating that it reflects a significant commitment from top-tier biotech investors who believe in the potential of APR-1051 to impact the lives of cancer patients. The company plans to enroll at least 50 patients in the study, focusing on populations where WEE1 inhibition may have meaningful therapeutic relevance. The private placement included the sale of pre-funded warrants to purchase approximately 37.2 million shares of common stock at a purchase price of $0.808 per warrant, and warrants to purchase an additional 37.2 million shares at an exercise price of $0.683 per share, which are exercisable immediately upon issuance and will expire on December 31, 2029. Aprea intends to file a registration statement with the SEC to register the resale of the securities purchased in the private placement. This financing is seen as a pivotal step in Aprea's strategy to enhance its clinical development path and generate insights in biomarker-defined patient populations likely to benefit from WEE1 inhibition.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.